metabolic dysfunction-associated steatohepatitis trials

FDA acceptance of VCTE as trial endpoint can accelerate MASH drug development: GlobalData

GlobalData notes FDA’s acceptance of VCTE as a surrogate endpoint may reduce reliance on biopsies, ease patient enrolment, and…